ClinicalTrials.gg
CompletedNCT07861841Updated Oct 6, 2026

The Influence of the Thoracic Stiffness of CPR Teaching Manikins on the Accuracy of Compression in Cardiopulmonary Resuscitation

An interventional study of different elasticity coefficients of the manikin device in Cardiac Arrest, Sudden, Cardiopulmonary Resuscitation (CPR) and Manikins, sponsored by Tang Ziren. Completed at 1 site in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Tang Ziren · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 9 years 8 months after the study started (first participant enrolled Jan 2017, registered Sep 2026).
Updated Oct 6, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
183
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Death, Sudden, Cardiac with a site in China — 9 open to participants now, 10 under way, none of them phase 3. Death, Sudden, Cardiac · China.

Started
2017
the only one that year
No phase
4 of 19
1 open now
Registered
19th of 19
by date

Among the 19 studies in Death, Sudden, Cardiac with a site in China, this one is the only one that started in 2017, is one of 4 with no phase, and was the 19th registered.

Death, Sudden, Cardiac

364 studies on the registry are indexed under Death, Sudden, Cardiac; 84 are open to participants now.

Browse Death, Sudden, Cardiac studies →

Open to participants now

9 of the 19 studies in Death, Sudden, Cardiac with a site in China are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 63 Death, Sudden, Cardiac studies recruiting now, 42 (67%) set no upper age limit and 11 (17%) stop at 75 or younger; 22 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Death, Sudden, Cardiac with a site in China, or all of them as a file.
02

Study summary

This study was a multicenter, prospective, randomized controlled, parallel single-blind study. The purpose of this study is to analyze the effect of compression quality by controlling the thoracic stiffness.

03

Conditions studied

  • Cardiac Arrest, Sudden
  • Cardiopulmonary Resuscitation (CPR)
  • Manikins
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • Able to read and write

Exclusion criteria

Exclusion Criteria:

  • Serious heart and lung disease
  • History of neuromuscular disease or injury
  • Female participants who are pregnant or potentially pregnant
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
183 participants (actual)

Study arms

  • Placebo comparator
    6N/mm group

    Other: different elasticity coefficients of the manikin device

  • Experimental
    8N/mm group

    Other: different elasticity coefficients of the manikin device

Interventions

  • Otherdifferent elasticity coefficients of the manikin device

    Different groups used different elasticity coefficients to record participants' compression depth, frequency during the process of ECC, and recorded the data of erroneous compression.

06

What researchers measure

Primary outcomes

  1. PCCR (percentage of correct compression rate)

    PCCR was defined as the percentage of chest compressions meeting guideline-recommended depth and rate criteria, calculated for each minute after initiation of chest compressions.

    Time frame: At 1, 2, 3, 4, 5, and 6 minutes after initiation of chest compressions

07

Study locations

1 site
  • Beijing Chao-Yang Hospital
    Beijing, Beijing Municipality 100020, China
08

References and documents

Individual participant data

Plan to share: Yes — All IPD that underlie results in a publication

Supporting information: Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Starting 6 months after publication

Access criteria: The de-identified survey data will be made available for research purposes by contacting the corresponding authors

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2017 to primary completion in Jun 2018, 17 months.

Of 47 non-industry interventional studies with no phase under Death, Sudden, Cardiac, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 86. This study's 17 months is below that.

Counting every sponsor, half of 56 studies reached it within 42 months; a quarter within 17 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2026
First posted
Oct 6, 2026
StartActual
Jan 1, 2017
Primary completionActual
Jun 1, 2018
CompletionActual
Sep 29, 2026
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07861841
Lead sponsor
Tang Ziren
Responsible party
Tang Ziren (Professor, Capital Medical University) — Sponsor-investigator
First posted
Oct 6, 2026
Start date
Jan 1, 2017
Primary completion
Jun 1, 2018
Completion
Sep 29, 2026
Last update
Oct 6, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion